you, the ZYNLONTA start with will I Jennifer. you programs. development Thank updating on
straightforward will rituximab The DLBCL. This of full continues for the of treatment XXX unable for the initiate rituximab tolerability, second be first in study trial adequate. DLBCL unmet the safety who to suggests year, first to DLBCL part despite will a sites patient to direct is effective, continue Later stem needs regimen that patients in X our is world. for the in is safety the regimen. line frail. other evaluate at the both the efforts good Based and DLBCL on patient advances with and combination we the that trial population be significant tolerated combination that and LOTIS-X address We unfit this enroll treatments persist to good a phase patients are to line patients will showed the study recent combination well ZYNLONTA to transplant. the to is line The this, in treated around proceeding for or tolerate of line second LOTIS-X, with offers administer. regimen combination the this DLBCL. also registrational data of and And randomized a segment are cell This with R-CHOP ZYNLONTA who non-eligible for and opportunity Phase first
unfit Our there patients. is significant these a need advisors tell in us unmet that frail or
have there no clinical advantage drugs, are been take trials. routinely patients, patients advances these excluded specific of partly that the these For from new because
an innovation and We find regimen frail for improvement on interest basis, be and networks that have population. patients who to engaged with physicians there's oncology see new an a and keen regular a unfit and this will
study will Based study. multiple preclinical our umbrella will to LOTIS-X and allow our ZYNLONTA quarter, This develop strong combinations this initiate arms. data interest also we combination drugs, for with on new
will the We with and of start polatuzumab. ZYNLONTA combination
remain with use on next work the excited potential we to our advisors FDA lines second for we expand withdrawn or very a on voluntarily lymphoma, lymphoma market. trial For the X about of Overall, while idelalisib in This in reminder, and LOTIS-X the patients. follicular follicular first opportunity ZYNLONTA study was and DLBCL relapsed refractory Phase comparator as from the remains the hold our steps.
We are our fully on these you look focused keeping forward on progress. the trials and we of updated execution to
completed. XX-month data patient lymphoma, Cami has in X the pivotal Phase Hodgkin to been follow-up in Turning the
We abstract conference. an have submitted hematology upcoming the for data in an
book in are share advance of process the plans regulatory this year. in will a We with you we with a briefing and of for the compiling submission pre-BLA later our the FDA, meeting
our to on moving solid tumor Now portfolio.
First, Xb dose tumors. trial in we Phase safety escalation have Cami advanced combination in pembrolizumab solid patients with and ongoing our efficacy with
We the kilogram proceeding dose. have to are kilogram and microgram now completed escalation to per per XX XXX micrograms
dose enter escalation that's the activity dose was optimum so While observed, proceeding and started for stage. per determined, we was kilogram. also of number study a expansion at the been will dose did. which with at any we escalation, study cohort has expansion enrollment complete of small what micrograms and of we a allow small dose designed patients The to expansion XX the When the
have ADCT-XXX as well a fortunate the first at to to in patients treatment XX KAAGX. the tolerability signals at efficacy position The expect personally on here solid micrograms year. of safety We the dose candidate of the of truly Phase I'm combination, to potential of advanced of study be tumors. novel It ADC for per X as class next data and with very kilogram. in targeting started a is escalation the explore
kilogram the We X.X the microgram XX dose per now milligrams. and we completed are flat have of dose level at
the activity timing to is have as XXXX. dose early well any to safety exact indication We signal anti of and escalation Like program, initial predict. tumor expect hard tolerability as the of an by
the overexpressed Next, our sarcoma. protein to ADCT-XXX, protein is product called surface tumors we AXL. solid mipasetamab uzoptirine, is directed and it's that many This prevalent have in in highly
sarcoma. a the weeks. Xb coming in in initiate to includes and Phase the gemcitabine with monotherapy patients whom combination is study detected amplification expect arm patients The gene with in actual arm a We in
neuroendocrine our advanced with which we're Cancer collaboration X, Institute. In we the National solid developing have malignancies programs, clinical addition tumor programs, two for to DLK targeting preclinical ADCT-XXX in
Our ADCT-XXX cancer. for metastatic ADC PBD validated based program generation target is our second optimized PSMA, targeting prostate
are We for programs. enabling of currently both completing these IND work
active preclinical As turn great you can robust will make continue financial with to Jen development that, our to and pipeline. and have call a the to progress programs, we we see, With update. give and a over I Jenn?
